EUVIMEDEUVIMED entdecken
Crossref

Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy

Haobing Wang, Yidan Lai, Dan Li, Johannes Karges iD, Pingyu Zhang iD, Huaiyi Huang iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c01889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Haobing Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antineoplastic Agents, Lung Neoplasms, Photochemotherapy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Science and Technology Foundation of Shenzhen City, Fonds der Chemischen Industrie, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Due to cell mutation and self-adaptation, the application of clinical drugs with early epidermal growth factor receptor (EGFR)-targeted inhibitors is severely limited. To overcome this limitation, herein, the synthesis and in-depth biological evaluation of an erlotinib-platinum(II) complex as an EGFR-targeted anticancer agent is reported. The metal complex is able to self-assemble inside an aqueous solution and readily form nanostructures with strong photophysical properties. While being poorly toxic toward healthy cells and upon treatment in the dark, the compound was able to induce a cytotoxic effect in the very low micromolar range upon irradiation against EGFR overexpressing (drug resistant) human lung cancer cells as well as multicellular tumor spheroids. Mechanistic insights revealed that the compound was able to selectively degrade the EGFR using the lysosomal degradation pathway upon generation of singlet oxygen at the EGFR. We are confident that this work will open new avenues for the treatment of EGFR-overexpressing tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAntineoplastic AgentsLung NeoplasmsPhotochemotherapyHumansErlotinib HydrochloridePlatinumErbB ReceptorsMutationProtein Kinase InhibitorsDrug Resistance, NeoplasmCell Line, Tumor

Substanzen

Erlotinib HydrochloridePlatinumAntineoplastic AgentsErbB ReceptorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • College of Chemistry and Environmental Engineering, Shenzhen University, Shenzhen 518060, China.
  • School of Pharmaceutical Science, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China.
  • Faculty of Chemistry and Biochemistry, Ruhr-University Bochum, Bochum 44780, Germany.

ORCID-Profile: Johannes Karges, Pingyu Zhang, Huaiyi Huang

Förderung

  • Science and Technology Foundation of Shenzhen City
  • Fonds der Chemischen Industrie
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Wang, H., Lai, Y., Li, D., Karges, J., Zhang, P., & Huang, H. (2024). Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01889

Vancouver

Wang H, Lai Y, Li D, Karges J, Zhang P, Huang H. Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c01889

BibTeX
@article{Wang2024,
  author = {Wang, Haobing and Lai, Yidan and Li, Dan and Karges, Johannes and Zhang, Pingyu and Huang, Huaiyi},
  title = {Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c01889}
}
Kostenlos starten →